RU2409591C2 - Удаление агрегатов с высокой молекулярной массой путем хроматографии на гидроксиапатитах - Google Patents
Удаление агрегатов с высокой молекулярной массой путем хроматографии на гидроксиапатитах Download PDFInfo
- Publication number
- RU2409591C2 RU2409591C2 RU2006113695/10A RU2006113695A RU2409591C2 RU 2409591 C2 RU2409591 C2 RU 2409591C2 RU 2006113695/10 A RU2006113695/10 A RU 2006113695/10A RU 2006113695 A RU2006113695 A RU 2006113695A RU 2409591 C2 RU2409591 C2 RU 2409591C2
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- buffer
- hydroxyapatite
- protein
- resin
- Prior art date
Links
- 229910052588 hydroxylapatite Inorganic materials 0.000 title claims abstract description 92
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 title claims abstract description 92
- 238000004587 chromatography analysis Methods 0.000 title claims abstract description 50
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 89
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 89
- 239000011347 resin Substances 0.000 claims abstract description 81
- 229920005989 resin Polymers 0.000 claims abstract description 81
- 238000000034 method Methods 0.000 claims abstract description 77
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 14
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 228
- 239000011780 sodium chloride Substances 0.000 claims description 114
- 239000000872 buffer Substances 0.000 claims description 70
- 230000027455 binding Effects 0.000 claims description 37
- 239000000758 substrate Substances 0.000 claims description 35
- 238000011068 loading method Methods 0.000 claims description 30
- 239000011534 wash buffer Substances 0.000 claims description 30
- 239000006167 equilibration buffer Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 238000005342 ion exchange Methods 0.000 claims description 25
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 23
- 239000007995 HEPES buffer Substances 0.000 claims description 22
- 239000004475 Arginine Substances 0.000 claims description 21
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 21
- 239000000356 contaminant Substances 0.000 claims description 20
- 239000003480 eluent Substances 0.000 claims description 20
- 239000000919 ceramic Substances 0.000 claims description 18
- 229910019142 PO4 Inorganic materials 0.000 claims description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 17
- 239000010452 phosphate Substances 0.000 claims description 17
- 239000012160 loading buffer Substances 0.000 claims description 15
- 238000005571 anion exchange chromatography Methods 0.000 claims description 13
- 238000005406 washing Methods 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 7
- 238000011026 diafiltration Methods 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 238000006073 displacement reaction Methods 0.000 claims 3
- 239000000178 monomer Substances 0.000 abstract description 24
- 238000010828 elution Methods 0.000 abstract description 12
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 239000001488 sodium phosphate Substances 0.000 description 86
- 229910000162 sodium phosphate Inorganic materials 0.000 description 86
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 86
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 75
- 238000002360 preparation method Methods 0.000 description 69
- 238000000746 purification Methods 0.000 description 44
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 30
- 229910000160 potassium phosphate Inorganic materials 0.000 description 15
- 235000011009 potassium phosphates Nutrition 0.000 description 15
- 238000003795 desorption Methods 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000001542 size-exclusion chromatography Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 10
- 238000004140 cleaning Methods 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 238000011403 purification operation Methods 0.000 description 8
- 230000005855 radiation Effects 0.000 description 8
- 238000005349 anion exchange Methods 0.000 description 7
- 239000012557 regeneration buffer Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 238000011010 flushing procedure Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000004472 Myostatin Human genes 0.000 description 5
- 108010056852 Myostatin Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 5
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011027 product recovery Methods 0.000 description 5
- 238000001742 protein purification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012149 elution buffer Substances 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012516 mab select resin Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 2
- 101100167365 Caenorhabditis elegans cha-1 gene Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- -1 sulfoethyl Chemical group 0.000 description 2
- 230000036964 tight binding Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000012562 protein A resin Substances 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 101150091813 shfl gene Proteins 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3847—Multimodal interactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/04—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
- B01J20/048—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium containing phosphorus, e.g. phosphates, apatites, hydroxyapatites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/282—Porous sorbents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51401803P | 2003-10-27 | 2003-10-27 | |
| US60/514,018 | 2003-10-27 | ||
| US52333503P | 2003-11-20 | 2003-11-20 | |
| US60/523,335 | 2003-11-20 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010139827/10A Division RU2573910C2 (ru) | 2003-10-27 | 2010-09-24 | Удаление агрегатов с высокой молекулярной массой путем хроматографии на гидроксиапатитах |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006113695A RU2006113695A (ru) | 2007-12-10 |
| RU2409591C2 true RU2409591C2 (ru) | 2011-01-20 |
Family
ID=34576743
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006113695/10A RU2409591C2 (ru) | 2003-10-27 | 2004-10-06 | Удаление агрегатов с высокой молекулярной массой путем хроматографии на гидроксиапатитах |
| RU2010139827/10A RU2573910C2 (ru) | 2003-10-27 | 2010-09-24 | Удаление агрегатов с высокой молекулярной массой путем хроматографии на гидроксиапатитах |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010139827/10A RU2573910C2 (ru) | 2003-10-27 | 2010-09-24 | Удаление агрегатов с высокой молекулярной массой путем хроматографии на гидроксиапатитах |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9469672B2 (enExample) |
| EP (2) | EP2336172B1 (enExample) |
| JP (2) | JP5004586B2 (enExample) |
| KR (2) | KR101221862B1 (enExample) |
| CN (2) | CN102276717B (enExample) |
| AU (1) | AU2004286938B2 (enExample) |
| BR (2) | BR122020007658B1 (enExample) |
| CA (1) | CA2543193C (enExample) |
| CO (1) | CO5690649A2 (enExample) |
| DK (2) | DK1678208T3 (enExample) |
| EC (1) | ECSP066583A (enExample) |
| ES (2) | ES2418830T3 (enExample) |
| IL (1) | IL175229A (enExample) |
| MX (1) | MXPA06004472A (enExample) |
| NZ (1) | NZ547315A (enExample) |
| PL (2) | PL2336172T3 (enExample) |
| PT (2) | PT1678208E (enExample) |
| RU (2) | RU2409591C2 (enExample) |
| WO (1) | WO2005044856A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2714967C2 (ru) * | 2013-12-27 | 2020-02-21 | Чугаи Сейяку Кабусики Кайся | Способ очистки антител с низкой изоэлектрической точкой |
| US10799589B2 (en) | 2013-03-13 | 2020-10-13 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0304576D0 (en) * | 2003-02-28 | 2003-04-02 | Lonza Biologics Plc | Protein a chromatography |
| BR122020007658B1 (pt) * | 2003-10-27 | 2021-07-27 | Wyeth | Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita |
| RU2457214C2 (ru) | 2005-03-11 | 2012-07-27 | Вайет | Способ хроматографии в режиме слабого распределения |
| EP1896504B1 (en) | 2005-06-17 | 2012-11-21 | Wyeth LLC | Methods of purifying fc region containing antibodies |
| JP2008546805A (ja) * | 2005-06-23 | 2008-12-25 | メディミューン，エルエルシー | 最適な凝集および断片化プロフィールを有する抗体製剤 |
| AR058140A1 (es) * | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| JP5405122B2 (ja) * | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| JPWO2007123242A1 (ja) | 2006-04-25 | 2009-09-10 | 東ソー株式会社 | ＩｇＧ精製用分離剤、及びそれを用いたＩｇＧ単量体の精製方法 |
| JP2010510963A (ja) * | 2006-06-14 | 2010-04-08 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | セラミックヒドロキシアパタイトを使用する抗体の精製方法 |
| PL2061803T5 (pl) | 2006-08-28 | 2023-03-27 | Ares Trading S.A. | Proces oczyszczania białek zawierających fc |
| CN101541825B (zh) * | 2006-08-28 | 2013-08-14 | 阿雷斯贸易股份有限公司 | Fc融合蛋白的纯化方法 |
| AU2007292253A1 (en) * | 2006-09-08 | 2008-03-13 | Wyeth | Arginine wash in protein purification using affinity chromatography |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| EP2500413A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| US7999085B2 (en) * | 2007-01-09 | 2011-08-16 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| ATE509107T1 (de) * | 2007-01-26 | 2011-05-15 | Merck Serono Sa | Aufreinigung von fc-tact-fusionsproteinen unter verwendung der ölkörper-technik |
| TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| CA2703086C (en) * | 2007-10-26 | 2014-11-25 | Asahi Kasei Chemicals Corporation | Method for purifying protein |
| US8188242B2 (en) * | 2008-04-08 | 2012-05-29 | Bio-Rad Laboratories, Inc. | Chromatography purification of antibodies |
| US10927144B2 (en) | 2008-08-14 | 2021-02-23 | Genentech, Inc. | Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography |
| SG10201702951RA (en) | 2008-10-20 | 2017-06-29 | Abbvie Inc | Viral inactivation during purification of antibodies |
| JP5808249B2 (ja) | 2008-10-20 | 2015-11-10 | アッヴィ・インコーポレイテッド | プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製 |
| EP4104821A1 (en) | 2008-10-29 | 2022-12-21 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| CA2739352C (en) * | 2008-10-29 | 2021-07-13 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
| CA2739568C (en) | 2008-10-31 | 2015-12-01 | Shujun Sun | Purification of acidic proteins using ceramic hydroxyapatite chromatography |
| CA2751000A1 (en) * | 2009-03-11 | 2010-12-23 | Wyeth Llc | Methods of purifying small modular immunopharmaceutical proteins |
| WO2010126979A1 (en) | 2009-04-29 | 2010-11-04 | Bio-Rad Laboratories, Inc. | Purification of immunoconjugates |
| US9441011B2 (en) | 2009-07-03 | 2016-09-13 | Asahi Kasei Chemicals Corporation | Method for purification of antibody using porous membrane having amino group and alkyl group both bound to graft chain immobilized on porous substrate |
| WO2011050071A2 (en) | 2009-10-20 | 2011-04-28 | Abbott Laboratories | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography |
| PL3272764T3 (pl) | 2009-12-18 | 2024-06-10 | Novartis Ag | Sposób chromatografii powinowactwa |
| US20130116413A1 (en) * | 2009-12-29 | 2013-05-09 | Dr. Reddy's Laboratories, Inc. | Purification of proteins |
| JP5773454B2 (ja) | 2010-01-15 | 2015-09-02 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | アパタイトの表面中和方法 |
| EP2558492B1 (en) | 2010-04-14 | 2016-11-16 | F.Hoffmann-La Roche Ag | Immunoglobulin aggregate removal |
| GB201006753D0 (en) | 2010-04-22 | 2010-06-09 | Biotest Ag | Process for preparing an immunolobulin composition |
| WO2011156073A1 (en) * | 2010-06-08 | 2011-12-15 | Millipore Corporation | Removal of protein aggregates from biopharmaceutical preparations using calcium phosphate salts |
| US8895707B2 (en) | 2010-08-18 | 2014-11-25 | Bio-Rad Laboratories, Inc. | Elution of proteins from hydroxyapatite resins without resin deterioration |
| AU2011325341B2 (en) | 2010-11-01 | 2015-12-17 | Dpx Holdings B.V. | Single unit ion exchange chromatography antibody purification |
| US9592540B2 (en) | 2011-02-02 | 2017-03-14 | Bio-Rad Laboratories, Inc. | Apatite surface neutralization with alkali solutions |
| SG195306A1 (en) * | 2011-06-08 | 2013-12-30 | Agency Science Tech & Res | Purification of biological products by constrained cohydration chromatography |
| WO2012171853A1 (en) * | 2011-06-16 | 2012-12-20 | Dsm Ip Assets B.V. | Single unit chromatography antibody purification |
| SG10201701224UA (en) * | 2012-03-12 | 2017-04-27 | Merck Patent Gmbh | Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode |
| EP2855501B1 (en) | 2012-05-30 | 2018-04-25 | Bio-Rad Laboratories, Inc. | In situ restoration of apatite-based chromatography resins |
| WO2014003142A1 (ja) * | 2012-06-27 | 2014-01-03 | 旭化成メディカル株式会社 | 抗体 |
| JP2014105180A (ja) * | 2012-11-27 | 2014-06-09 | Hoya Corp | モノマー化方法 |
| WO2014209508A1 (en) * | 2013-05-13 | 2014-12-31 | Medimmune, Llc | Separation of recombinant polyclonal antibody multimers with minimal separation of monomers |
| ES2793176T3 (es) | 2013-07-05 | 2020-11-13 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa | Matriz de cromografía de afinidad |
| JP6479305B2 (ja) * | 2013-07-12 | 2019-03-06 | 株式会社Ｕｍｎファーマ | ウイルス様粒子の精製方法 |
| EP3019262A1 (en) | 2013-07-12 | 2016-05-18 | Merck Patent GmbH | Removal of fragments from a sample containing a target protein using activated carbon |
| WO2015088677A1 (en) | 2013-12-12 | 2015-06-18 | Emd Millipore Corporation | Protein separations using an acrylamide containing filter |
| WO2015200278A1 (en) | 2014-06-23 | 2015-12-30 | Bio-Rad Laboratories, Inc. | Apatite in-situ restoration |
| EP3157689B1 (en) | 2014-06-23 | 2021-04-28 | Bio-Rad Laboratories, Inc. | Apatite pretreatment |
| CN107001411B (zh) | 2014-12-15 | 2021-07-23 | 默克专利股份公司 | 从粗溶液捕获靶分子 |
| EA035635B1 (ru) | 2015-03-13 | 2020-07-17 | Бристол-Маерс Сквибб Компани | Использование щелочных промывочных растворов во время хроматографии для удаления примесей |
| ES2817751T3 (es) | 2015-12-21 | 2021-04-08 | Pfizer | Purificación de conjugados de anticuerpo-fármaco mediante el uso de un gradiente de fosfato de sodio |
| US11919924B1 (en) * | 2016-03-15 | 2024-03-05 | Fresenius Kabi Deutschland Gmbh | Methods of purifying and producing an adalimumab antibody |
| US11186858B1 (en) | 2016-03-15 | 2021-11-30 | Fresenius Kabi Deutschland Gmbh | Methods for increasing biosimilarity |
| CN106977591B (zh) * | 2017-05-04 | 2020-05-05 | 广州康盛生物科技股份有限公司 | 一种分离纯化重组葡萄球菌蛋白a的方法 |
| EP3672981A4 (en) * | 2017-08-22 | 2021-09-15 | Biogen MA Inc. | PROCESSES FOR PURIFYING ANTIBODIES PRESENTING REDUCED AGGREGATES WITH HIGH MOLECULAR WEIGHT |
| WO2019116096A1 (en) * | 2017-12-15 | 2019-06-20 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Production of fc fragments |
| US20210017254A1 (en) * | 2018-02-27 | 2021-01-21 | Pfizer Inc. | Antibody Purification |
| CN119881293A (zh) | 2018-03-21 | 2025-04-25 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| WO2019192877A1 (en) | 2018-04-03 | 2019-10-10 | Merck Patent Gmbh | Cex chromatography media and low salt elution of target proteins from biopharmaceutical feeds |
| WO2019224660A1 (ja) * | 2018-05-24 | 2019-11-28 | ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 | 吸着剤の生産方法 |
| JP6704074B2 (ja) * | 2019-02-04 | 2020-06-03 | 株式会社Ｕｍｎファーマ | ウイルス様粒子の精製方法 |
| WO2021099536A1 (en) | 2019-11-22 | 2021-05-27 | Morphosys Ag | Method to increase antibody yield during ion exchange chromatography |
| JP2020099909A (ja) * | 2020-03-17 | 2020-07-02 | ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 | 処理方法、生産方法およびハイドロキシアパタイト充填剤 |
| MX2022012278A (es) | 2020-03-30 | 2022-10-27 | Ablynx Nv | Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes. |
| CA3182368A1 (en) | 2020-05-01 | 2021-11-04 | Kashiv Biosciences, Llc | An improved process of purification of protein |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US523335A (en) | 1894-07-24 | Air-bolt for flour-mills | ||
| US514018A (en) | 1894-02-06 | Edward j | ||
| US419964A (en) | 1890-01-21 | Transom-lifter | ||
| US428894A (en) | 1890-05-27 | Process of making tool-handles | ||
| US4745183A (en) * | 1984-02-21 | 1988-05-17 | Bio-Rad Laboratories, Inc. | Use of hydroxylapatite for the analysis and preparation of purified monoclonal antibodies |
| JPH03291300A (ja) * | 1989-12-28 | 1991-12-20 | Mitsui Toatsu Chem Inc | ポリクローナル抗体の分離方法 |
| GB9022545D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| JP4363986B2 (ja) * | 2001-12-21 | 2009-11-11 | イミュネックス・コーポレーション | タンパク質の精製方法 |
| EP1601697B1 (en) | 2003-02-28 | 2007-05-30 | Lonza Biologics plc | Antibody purification by Protein A and ion exchange chromatography |
| BR122020007658B1 (pt) * | 2003-10-27 | 2021-07-27 | Wyeth | Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita |
-
2004
- 2004-10-06 BR BR122020007658-5A patent/BR122020007658B1/pt active IP Right Grant
- 2004-10-06 EP EP10174366.4A patent/EP2336172B1/en not_active Expired - Lifetime
- 2004-10-06 PT PT47942883T patent/PT1678208E/pt unknown
- 2004-10-06 ES ES04794288T patent/ES2418830T3/es not_active Expired - Lifetime
- 2004-10-06 CN CN201110221442.5A patent/CN102276717B/zh not_active Expired - Lifetime
- 2004-10-06 PL PL10174366T patent/PL2336172T3/pl unknown
- 2004-10-06 US US10/958,595 patent/US9469672B2/en active Active
- 2004-10-06 EP EP04794288.3A patent/EP1678208B1/en not_active Expired - Lifetime
- 2004-10-06 PT PT101743664T patent/PT2336172E/pt unknown
- 2004-10-06 DK DK04794288.3T patent/DK1678208T3/da active
- 2004-10-06 KR KR1020067010375A patent/KR101221862B1/ko not_active Expired - Lifetime
- 2004-10-06 KR KR1020117030940A patent/KR101321876B1/ko not_active Expired - Lifetime
- 2004-10-06 RU RU2006113695/10A patent/RU2409591C2/ru active
- 2004-10-06 ES ES10174366T patent/ES2530446T3/es not_active Expired - Lifetime
- 2004-10-06 PL PL04794288T patent/PL1678208T3/pl unknown
- 2004-10-06 CA CA2543193A patent/CA2543193C/en not_active Expired - Fee Related
- 2004-10-06 JP JP2006538022A patent/JP5004586B2/ja not_active Expired - Lifetime
- 2004-10-06 BR BRPI0415887-3A patent/BRPI0415887B1/pt not_active IP Right Cessation
- 2004-10-06 WO PCT/US2004/032883 patent/WO2005044856A2/en not_active Ceased
- 2004-10-06 AU AU2004286938A patent/AU2004286938B2/en not_active Expired
- 2004-10-06 MX MXPA06004472A patent/MXPA06004472A/es active IP Right Grant
- 2004-10-06 NZ NZ547315A patent/NZ547315A/en unknown
- 2004-10-06 CN CN2004800387536A patent/CN1898266B/zh not_active Expired - Lifetime
- 2004-10-06 DK DK10174366.4T patent/DK2336172T3/en active
-
2006
- 2006-04-26 IL IL175229A patent/IL175229A/en active IP Right Grant
- 2006-05-19 CO CO06048228A patent/CO5690649A2/es not_active Application Discontinuation
- 2006-05-25 EC EC2006006583A patent/ECSP066583A/es unknown
-
2010
- 2010-09-24 RU RU2010139827/10A patent/RU2573910C2/ru active
-
2012
- 2012-01-26 JP JP2012013648A patent/JP5490156B2/ja not_active Expired - Lifetime
-
2013
- 2013-03-14 US US13/803,071 patent/US9822143B2/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| GIOVANNINI R. et al., "Comparison of different types of ceramic hydroxyapatite for the chromatographic separation ofplasmid DNA and a recombinant anti-rhesus D antibody", Bioseparation. 2000; 9(6): 359-68. GIOVANNINI R. et al., "Isolation of a recombinant antibody from cell culture supernatant: continuous annular versus batch and expanded-bed chromatography", Biotechnol Bioeng. 2001 Jun 20; 73(6): 522-9. * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10799589B2 (en) | 2013-03-13 | 2020-10-13 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
| RU2714967C2 (ru) * | 2013-12-27 | 2020-02-21 | Чугаи Сейяку Кабусики Кайся | Способ очистки антител с низкой изоэлектрической точкой |
| US10654933B2 (en) | 2013-12-27 | 2020-05-19 | Chugai Seiyaku Kabushiki Kaisha | Method for purifying antibody having low isoelectric point |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2409591C2 (ru) | Удаление агрегатов с высокой молекулярной массой путем хроматографии на гидроксиапатитах | |
| KR101482791B1 (ko) | 약한 분배성 크로마토그래피법 | |
| KR101921552B1 (ko) | 사전 세정 단계를 이용하는 면역글로불린 정제 | |
| CN102977182B (zh) | 在蛋白质纯化过程中降低样品中的一种或多种杂质水平的方法 | |
| KR101243425B1 (ko) | 항체의 정제 방법 | |
| JP5243450B2 (ja) | 水溶性の非イオン性有機高分子の存在下での混合モードクロマトグラフィーによる抗体の能力の増大および精製方法 | |
| HU217850B (hu) | Eljárás antitest tisztítására | |
| CN101043947B (zh) | 一种纯化抗体的方法 |